STOCK TITAN

Hyperfine, Inc. - HYPR STOCK NEWS

Welcome to our dedicated page for Hyperfine news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on Hyperfine stock.

Hyperfine, Inc. (Nasdaq: HYPR) is committed to revolutionizing the field of medical imaging with its pioneering Swoop® Portable MR Imaging System™. By making MRI accessible to every patient, regardless of income or location, Hyperfine is bridging the gap in medical imaging. The Swoop system addresses the limitations of conventional MRI scanners by providing portable, bedside imaging capabilities. This breakthrough technology plugs into a standard electrical outlet and is controlled using an Apple iPad®, displaying images within minutes. This efficiency aids critical decision-making in diverse clinical settings such as neurointensive care units, emergency departments, and pediatric wards.

Designed to complement traditional MRI systems, the Swoop Portable MR Imaging System can be operated by new users with just 30 minutes of training, streamlining workflows and enhancing patient care. The system is cost-effective, with the complete Swoop package costing less than the annual service contract of most fixed MRI systems.

Since receiving FDA clearance in August 2020 for brain and head imaging, Hyperfine has achieved significant milestones. The company has expanded its market reach, gaining approvals in several countries including Canada, Australia, the United Kingdom, and the European Union. Hyperfine’s recent achievements include the successful enrollment in the CARE PMR study for Alzheimer’s and the introduction of its 8th generation AI-powered software.

In the first quarter of 2024, Hyperfine reported strong commercial progress and financial results, demonstrating their ability to meet critical milestones while maintaining spending discipline. The company remains focused on its core values of commercialization, clinical evidence, and innovation. Under the leadership of CEO Maria Sainz, Hyperfine continues to push the boundaries of medical imaging technology, aiming to provide accessible and clinically relevant diagnostic imaging solutions globally.

For more information, visit Hyperfine's Investor Relations.

Rhea-AI Summary
Hyperfine, Inc. (HYPR) reported strong growth in 2023, achieving $11.03 million in revenues, up 62% from 2022. The company sold 37 Swoop® systems in 2023, with a net loss of $44.24 million. Hyperfine received multiple certifications, launched new programs, and reduced cash burn to extend cash runway. Fourth quarter 2023 revenues were $2.69 million, up 89% from the previous year. The company sold seven Swoop® systems in Q4 2023, with a net loss of $10.68 million. Management expects 2024 revenue to reach $12 to $15 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) showcases the first FDA-cleared portable MR brain imaging system to The Princess Royal, highlighting its use in testing MR access disparities in low- and medium-resource countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) will report financial results for Q4 and full year 2023 on March 21, 2024. The company, known for its portable MR brain imaging system, Swoop®, has redefined brain imaging technology. The conference call will be hosted by management at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live webcast on Hyperfine's Investors page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) collaborates with Athletic Heart to provide portable brain imaging screenings to professional athletes, starting with retired basketball players. The partnership aims to enhance brain health insights for athletes through the use of the Swoop® Portable MR Imaging® system. The inaugural event took place at the 2024 All-Star game in Indianapolis, showcasing the commitment to accessible and comprehensive medical care for athletes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced the presentation of four abstracts at the 2024 International Stroke Conference, showcasing the clinical utility and applications of portable ultra-low-field MR imaging. The Swoop® system aims to transform the diagnosis and treatment of acute ischemic stroke. The company also provided an update on the enrollment progress of the ACTION PMR study, which aims to integrate brain imaging with the Swoop® system into the stroke diagnosis and treatment workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) has obtained CE and UKCA approval for the eighth generation of Swoop® system software, which includes AI-powered features such as DWI denoising. The software has been well-received by users, improving image quality and workflow efficiencies. With international certifications, the company is poised for global expansion, aiming to bring the Swoop® system to a broader market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
AI
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting. The studies analyzed how portable MR brain imaging may assist in the diagnosis and management of neurological conditions in critical care settings, showcasing the potential of portable ultra-low-field brain imaging to improve brain health. The sessions will cover topics such as longitudinal relaxivity estimation of contrast agents, generative adversarial network approach for low-field to high-field image translation, and preliminary results from a single-center retrospective study in the neurocritical care setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces participation in the Piper Sandler 35th Annual Healthcare Conference in New York. The company will present its groundbreaking FDA-cleared portable MRI brain imaging system, the Swoop® system, on November 30, 2023, at 9:30 am PT. A live webcast and archived recording will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
conferences
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced third quarter 2023 financial results, with revenues of $2.33 million, six commercial Swoop® systems sold, and a net loss of $10.76 million. The company also provided a business update, including FDA clearance for new AI-powered software and progress in clinical programs such as an upcoming Alzheimer's feasibility study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.37%
Tags

FAQ

What is the current stock price of Hyperfine (HYPR)?

The current stock price of Hyperfine (HYPR) is $0.8851 as of December 20, 2024.

What is the market cap of Hyperfine (HYPR)?

The market cap of Hyperfine (HYPR) is approximately 66.7M.

What is Hyperfine's mission?

Hyperfine’s mission is to make MRI accessible to every patient, regardless of income or resources, anytime, anywhere.

What is the Swoop® Portable MR Imaging System?

The Swoop system is a portable MRI device that wheels directly to a patient's bedside, plugs into a standard outlet, and uses an iPad® for control, displaying images within minutes.

When did Swoop receive FDA clearance?

The Swoop Portable MR Imaging System received FDA clearance in August 2020 for brain and head imaging.

What are the core values of Hyperfine?

Hyperfine's core values focus on commercialization, clinical evidence, and innovation.

How long does it take to train new users on the Swoop system?

New users can be trained on the Swoop system operation, device navigation, and safety in about 30 minutes.

What are the cost benefits of the Swoop system?

The complete Swoop Portable MR Imaging System costs less than the annual service contract for most fixed conventional MRI systems.

Where is the Swoop system currently approved for use?

The Swoop system is approved for use in the United States, Canada, Australia, the United Kingdom, and the European Union.

What recent achievements has Hyperfine made?

Recent achievements include the commencement of the CARE PMR study in Alzheimer's and the launch of the 8th generation AI-powered software.

Who is the CEO of Hyperfine, Inc.?

The CEO of Hyperfine, Inc. is Maria Sainz.

Where can I find more information about Hyperfine?

More information about Hyperfine can be found on their investor relations page at https://investors.hyperfine.io/.

Hyperfine, Inc.

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

66.75M
52.43M
9.5%
24.35%
2.14%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GUILFORD